GoAI
Get started
Agilon Health, Inc. logo

Agilon Health, Inc.

AGL

NYSEHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$96.58

+$3.85 · +4.15%

Aug 21, 4:00 PM ET

AGL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

34

Expensive

Momentum

60

Neutral

Sentiment

48

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
Timothy O'Rourke
Listed since
Apr 15, 2021
Employees
856

Market position

Day range

Current $96.58

52-week range

Current $96.58

Open
$94.12
Previous close
$92.73
Volume
277.39K
0.69× average
Average volume
403.23K
Average daily volume
Market cap
1.61B USD
Beta
3.05
Market reference 1
50-day average
$106.08
-8.95% below average
200-day average
$47.7859
+102.11% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
148.24M USD
P/E (TTM)
-6.28×
P/B (TTM)
7.09×
P/S (TTM)
0.27×
EV / EBITDA
-0.4×
Earnings yield
-142.16%
Free cash flow yield
-41.74%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
-4.48%
Net margin
-4.24%
Return on equity
-319.84%
Return on assets
-31.88%
Return on invested capital
-196.72%

Financial health

Debt / equity
0.15×
Current ratio
1.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends8%-5%-17%-30%Gross margin, FY2021: 4.32%Gross margin, FY2022: 4.66%Gross margin, FY2023: 1.61%Gross margin, FY2024: 0.08%Gross margin, FY2025: -3.18%Operating margin, FY2021: -24.47%Operating margin, FY2022: -4.41%Operating margin, FY2023: -5.38%Operating margin, FY2024: -4.82%Operating margin, FY2025: -7.10%Net margin, FY2021: -26.72%Net margin, FY2022: -4.46%Net margin, FY2023: -6.08%Net margin, FY2024: -4.29%Net margin, FY2025: -6.83%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 4.32%. Gross margin FY2022 4.66%. Gross margin FY2023 1.61%. Gross margin FY2024 0.08%. Gross margin FY2025 -3.18%. Operating margin FY2021 -24.47%. Operating margin FY2022 -4.41%. Operating margin FY2023 -5.38%. Operating margin FY2024 -4.82%. Operating margin FY2025 -7.10%. Net margin FY2021 -26.72%. Net margin FY2022 -4.46%. Net margin FY2023 -6.08%. Net margin FY2024 -4.29%. Net margin FY2025 -6.83%.

Income trends

Revenue

5.93B USD-2.11%

Operating income

−421.08M USD-44.14%

Net income

−405.35M USD-55.81%
Income trends across reported periods6.71B USD4.12B USD1.52B USD−1.07B USDRevenue, FY2021: 1.52B USDRevenue, FY2022: 2.39B USDRevenue, FY2023: 4.32B USDRevenue, FY2024: 6.06B USDRevenue, FY2025: 5.93B USDOperating income, FY2021: −372.24M USDOperating income, FY2022: −105.38M USDOperating income, FY2023: −232.13M USDOperating income, FY2024: −292.13M USDOperating income, FY2025: −421.08M USDNet income, FY2021: −406.49M USDNet income, FY2022: −106.55M USDNet income, FY2023: −262.6M USDNet income, FY2024: −260.15M USDNet income, FY2025: −405.35M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.52B USD. Revenue FY2022 2.39B USD. Revenue FY2023 4.32B USD. Revenue FY2024 6.06B USD. Revenue FY2025 5.93B USD. Operating income FY2021 −372.24M USD. Operating income FY2022 −105.38M USD. Operating income FY2023 −232.13M USD. Operating income FY2024 −292.13M USD. Operating income FY2025 −421.08M USD. Net income FY2021 −406.49M USD. Net income FY2022 −106.55M USD. Net income FY2023 −262.6M USD. Net income FY2024 −260.15M USD. Net income FY2025 −405.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue5.93B USD6.06B USD4.32B USD2.39B USD1.52B USD
Cost of goods sold6.12B USD6.06B USD4.25B USD2.28B USD1.46B USD
Gross profit−188.61M USD4.84M USD69.67M USD111.36M USD65.74M USD
Selling, general, and administrative238.54M USD268.91M USD285.76M USD207.79M USD427.5M USD
Operating expenses232.46M USD296.97M USD301.8M USD216.74M USD437.99M USD
Interest expense6.64M USD6.18M USD6.66M USD4.48M USD6.15M USD
Depreciation and amortization28.59M USD24.46M USD20.16M USD13.77M USD14.67M USD
Operating income−421.08M USD−292.13M USD−232.13M USD−105.38M USD−372.24M USD
Net income−405.35M USD−260.15M USD−262.6M USD−106.55M USD−406.49M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-512.47%
11 comparable reports
Latest EPS result
1.04
Estimate 0.14 · Beat by 622.22%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.86-2.28-7.42-12.56Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -6.5, estimate -0.18, surprise -3511.11%, Miss. Q2 2025, reported May 6, 2025: actual 0.733, estimate -0.075, surprise +1082.44%, Beat. Q3 2025, reported Aug 5, 2025: actual -6.25, estimate -2.75, surprise -127.27%, Miss. Q4 2025, reported Nov 4, 2025: actual -6.75, estimate -3.73, surprise -80.73%, Miss. Q1 2026, reported Feb 25, 2026: actual -11.5, estimate -6.75, surprise -70.37%, Miss. Q2 2026, reported May 6, 2026: actual 1.8, estimate 1.13, surprise +59.29%, Beat. Q3 2026, reported Aug 5, 2026: actual 1.04, estimate 0.144, surprise +622.22%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate -1.18, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.63B1.53B1.42B1.32BQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 1.52B USD, estimate 1.52B USD, surprise +0.26%, Beat. Q2 2025, reported May 6, 2025: actual 1.53B USD, estimate 1.5B USD, surprise +1.93%, Beat. Q3 2025, reported Aug 5, 2025: actual 1.39B USD, estimate 1.47B USD, surprise -5.22%, Miss. Q4 2025, reported Nov 4, 2025: actual 1.44B USD, estimate 1.42B USD, surprise +0.95%, Beat. Q1 2026, reported Feb 25, 2026: actual 1.57B USD, estimate 1.47B USD, surprise +6.85%, Beat. Q2 2026, reported May 6, 2026: actual 1.42B USD, estimate 1.38B USD, surprise +2.94%, Beat. Q3 2026, reported Aug 5, 2026: actual 1.49B USD, estimate 1.45B USD, surprise +3.03%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 1.46B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$85.43

11.54% downside
Past 12 months12-month forecastHigh $146Average $85.43Low $16.00

Recent analyst actions

12 institutions

Corporate actions

Corporate action history

Dividend

Ex-dividend Nov 16, 2011

$0.018

Quarterly

Payment Dec 1, 2011

Dividend

Ex-dividend Aug 17, 2011

$0.018

Quarterly

Payment Sep 1, 2011

AGL peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

Continue in GoAI

Research AGL

research.disclaimer